-
1
-
-
84939518267
-
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
-
Antonia S, Bendell J, Taylor M, Calvo E, Jaeger D, De Braud F, Ott P, Pietanza M, Horn L, Le D, Morse M, Lopez-Martin J, Ascierto P, Christensen O, Grosso J, Simon J, Lin C, Eder J (2015) Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol 33(15_suppl):abstr 7503
-
(2015)
J Clin Oncol 33(15_suppl):abstr
, pp. 7503
-
-
Antonia, S.1
Bendell, J.2
Taylor, M.3
Calvo, E.4
Jaeger, D.5
De Braud, F.6
Ott, P.7
Pietanza, M.8
Horn, L.9
Le, D.10
Morse, M.11
Lopez-Martin, J.12
Ascierto, P.13
Christensen, O.14
Grosso, J.15
Simon, J.16
Lin, C.17
Eder, J.18
-
2
-
-
0035049158
-
Adjusting for multiple testing—when and how?
-
COI: 1:STN:280:DC%2BD3M3gvFaltg%3D%3D, PID: 11297884
-
Bender R, Lange S (2001) Adjusting for multiple testing—when and how? J Clin Epidemiol 54(4):343–349
-
(2001)
J Clin Epidemiol
, vol.54
, Issue.4
, pp. 343-349
-
-
Bender, R.1
Lange, S.2
-
3
-
-
84991549033
-
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
-
Berghoff A, Schur S, Füreder L, Gatterbauer B, Dieckmann K, Widhalm G, Hainfellner J, Zielinski C, Birner P, Bartsch R, Preusser M (2016) Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open 1. doi:10.1136/esmoopen-2015-000024
-
(2016)
ESMO Open 1
-
-
Berghoff, A.1
Schur, S.2
Füreder, L.3
Gatterbauer, B.4
Dieckmann, K.5
Widhalm, G.6
Hainfellner, J.7
Zielinski, C.8
Birner, P.9
Bartsch, R.10
Preusser, M.11
-
4
-
-
84954429886
-
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
-
Berghoff A, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M (2016) Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 5(1):e105738
-
(2016)
Oncoimmunology
, vol.5
, Issue.1
-
-
Berghoff, A.1
Fuchs, E.2
Ricken, G.3
Mlecnik, B.4
Bindea, G.5
Spanberger, T.6
Hackl, M.7
Widhalm, G.8
Dieckmann, K.9
Prayer, D.10
Bilocq, A.11
Heinzl, H.12
Zielinski, C.13
Bartsch, R.14
Birner, P.15
Galon, J.16
Preusser, M.17
-
5
-
-
84880924090
-
Lack of BRAF V600E protein expression in primary central nervous system lymphoma
-
COI: 1:CAS:528:DC%2BC3sXpsFKiu7Y%3D, PID: 23235345
-
Berghoff AS, Capper D, Preusser M (2013) Lack of BRAF V600E protein expression in primary central nervous system lymphoma. Appl Immunohistochem Mol Morphol 21(4):351–353. doi:10.1097/PAI.0b013e3182688e59
-
(2013)
Appl Immunohistochem Mol Morphol
, vol.21
, Issue.4
, pp. 351-353
-
-
Berghoff, A.S.1
Capper, D.2
Preusser, M.3
-
6
-
-
84954429886
-
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
-
PID: 26942067
-
Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M (2016) Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. doi:10.1080/2162402X.2015.1057388
-
(2016)
Oncoimmunology
-
-
Berghoff, A.S.1
Fuchs, E.2
Ricken, G.3
Mlecnik, B.4
Bindea, G.5
Spanberger, T.6
Hackl, M.7
Widhalm, G.8
Dieckmann, K.9
Prayer, D.10
Bilocq, A.11
Heinzl, H.12
Zielinski, C.13
Bartsch, R.14
Birner, P.15
Galon, J.16
Preusser, M.17
-
7
-
-
84943241524
-
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
-
PID: 25355681
-
Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W (2014) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. doi:10.1093/neuonc/nou307
-
(2014)
Neuro Oncol
-
-
Berghoff, A.S.1
Kiesel, B.2
Widhalm, G.3
Rajky, O.4
Ricken, G.5
Wohrer, A.6
Dieckmann, K.7
Filipits, M.8
Brandstetter, A.9
Weller, M.10
Kurscheid, S.11
Hegi, M.E.12
Zielinski, C.C.13
Marosi, C.14
Hainfellner, J.A.15
Preusser, M.16
Wick, W.17
-
8
-
-
84960343832
-
The inflammatory microenvironment in brain metastases: potential treatment target?
-
PID: 26112807
-
Berghoff AS, Preusser M (2015) The inflammatory microenvironment in brain metastases: potential treatment target? Chin Clin Oncol 4(2):21. doi:10.3978/j.issn.2304-3865.2015.06.03
-
(2015)
Chin Clin Oncol
, vol.4
, Issue.2
, pp. 21
-
-
Berghoff, A.S.1
Preusser, M.2
-
9
-
-
84925266488
-
Tumor infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases
-
Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Holler C, Preusser M (2014) Tumor infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology. doi:10.1111/his.12537
-
(2014)
Histopathology
-
-
Berghoff, A.S.1
Ricken, G.2
Widhalm, G.3
Rajky, O.4
Dieckmann, K.5
Birner, P.6
Bartsch, R.7
Holler, C.8
Preusser, M.9
-
10
-
-
84891654921
-
PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)
-
PID: 24359606
-
Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, Raderer M, Preusser M (2014) PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol 33(1):42–49
-
(2014)
Clin Neuropathol
, vol.33
, Issue.1
, pp. 42-49
-
-
Berghoff, A.S.1
Ricken, G.2
Widhalm, G.3
Rajky, O.4
Hainfellner, J.A.5
Birner, P.6
Raderer, M.7
Preusser, M.8
-
11
-
-
84944937210
-
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
-
PID: 26412456
-
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. doi:10.1056/NEJMoa1507643
-
(2015)
N Engl J Med
-
-
Borghaei, H.1
Paz-Ares, L.2
Horn, L.3
Spigel, D.R.4
Steins, M.5
Ready, N.E.6
Chow, L.Q.7
Vokes, E.E.8
Felip, E.9
Holgado, E.10
Barlesi, F.11
Kohlhaufl, M.12
Arrieta, O.13
Burgio, M.A.14
Fayette, J.15
Lena, H.16
Poddubskaya, E.17
Gerber, D.E.18
Gettinger, S.N.19
Rudin, C.M.20
Rizvi, N.21
Crino, L.22
Blumenschein, G.R.23
Antonia, S.J.24
Dorange, C.25
Harbison, C.T.26
Graf Finckenstein, F.27
Brahmer, J.R.28
more..
-
12
-
-
84936791837
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
-
COI: 1:CAS:528:DC%2BC2MXht12qu7%2FJ, PID: 26028407
-
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. doi:10.1056/NEJMoa1504627
-
(2015)
N Engl J Med
, vol.373
, Issue.2
, pp. 123-135
-
-
Brahmer, J.1
Reckamp, K.L.2
Baas, P.3
Crino, L.4
Eberhardt, W.E.5
Poddubskaya, E.6
Antonia, S.7
Pluzanski, A.8
Vokes, E.E.9
Holgado, E.10
Waterhouse, D.11
Ready, N.12
Gainor, J.13
Aren Frontera, O.14
Havel, L.15
Steins, M.16
Garassino, M.C.17
Aerts, J.G.18
Domine, M.19
Paz-Ares, L.20
Reck, M.21
Baudelet, C.22
Harbison, C.T.23
Lestini, B.24
Spigel, D.R.25
more..
-
13
-
-
84953445855
-
Trial watch: immunomodulatory monoclonal antibodies for oncological indications
-
PID: 26137403
-
Buque A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L (2015) Trial watch: immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 4(4):e1008814. doi:10.1080/2162402X.2015.1008814
-
(2015)
Oncoimmunology
, vol.4
, Issue.4
-
-
Buque, A.1
Bloy, N.2
Aranda, F.3
Castoldi, F.4
Eggermont, A.5
Cremer, I.6
Fridman, W.H.7
Fucikova, J.8
Galon, J.9
Marabelle, A.10
Spisek, R.11
Tartour, E.12
Zitvogel, L.13
Kroemer, G.14
Galluzzi, L.15
-
14
-
-
79959580390
-
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
-
COI: 1:CAS:528:DC%2BC3MXnvVKnsr0%3D, PID: 21638088
-
Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122(1):11–19. doi:10.1007/s00401-011-0841-z
-
(2011)
Acta Neuropathol
, vol.122
, Issue.1
, pp. 11-19
-
-
Capper, D.1
Preusser, M.2
Habel, A.3
Sahm, F.4
Ackermann, U.5
Schindler, G.6
Pusch, S.7
Mechtersheimer, G.8
Zentgraf, H.9
von Deimling, A.10
-
15
-
-
84857030136
-
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
-
COI: 1:CAS:528:DC%2BC38XpslyktA%3D%3D, PID: 22012135
-
Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, Hackl M, Pichler J, Pusch S, Meyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M (2012) Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 123(2):223–233. doi:10.1007/s00401-011-0887-y
-
(2012)
Acta Neuropathol
, vol.123
, Issue.2
, pp. 223-233
-
-
Capper, D.1
Berghoff, A.S.2
Magerle, M.3
Ilhan, A.4
Wohrer, A.5
Hackl, M.6
Pichler, J.7
Pusch, S.8
Meyer, J.9
Habel, A.10
Petzelbauer, P.11
Birner, P.12
von Deimling, A.13
Preusser, M.14
-
16
-
-
84871192340
-
Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1
-
COI: 1:CAS:528:DC%2BC38XhvFSiurbL, PID: 23087408
-
Chen DS, Irving BA, Hodi FS (2012) Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18(24):6580–6587. doi:10.1158/1078-0432.CCR-12-1362
-
(2012)
Clin Cancer Res
, vol.18
, Issue.24
, pp. 6580-6587
-
-
Chen, D.S.1
Irving, B.A.2
Hodi, F.S.3
-
17
-
-
79955622234
-
Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor
-
COI: 1:CAS:528:DC%2BC3MXlsVeqsLg%3D, PID: 21240258
-
Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegard J, Palmqvist R (2011) Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 24(5):671–682. doi:10.1038/modpathol.2010.234
-
(2011)
Mod Pathol
, vol.24
, Issue.5
, pp. 671-682
-
-
Dahlin, A.M.1
Henriksson, M.L.2
Van Guelpen, B.3
Stenling, R.4
Oberg, A.5
Rutegard, J.6
Palmqvist, R.7
-
18
-
-
84957667954
-
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
-
PID: 26625204
-
Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Johrens K (2016) Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 7(2):1486–1499. doi:10.18632/oncotarget.6429
-
(2016)
Oncotarget
, vol.7
, Issue.2
, pp. 1486-1499
-
-
Darb-Esfahani, S.1
Kunze, C.A.2
Kulbe, H.3
Sehouli, J.4
Wienert, S.5
Lindner, J.6
Budczies, J.7
Bockmayr, M.8
Dietel, M.9
Denkert, C.10
Braicu, I.11
Johrens, K.12
-
19
-
-
84862868501
-
B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels
-
COI: 1:CAS:528:DC%2BC38XovVyrsbg%3D, PID: 22661084
-
Durand-Panteix S, Farhat M, Youlyouz-Marfak I, Rouaud P, Ouk-Martin C, David A, Faumont N, Feuillard J, Jayat-Vignoles C (2012) B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. J Immunol 189(1):181–190. doi:10.4049/jimmunol.1102277
-
(2012)
J Immunol
, vol.189
, Issue.1
, pp. 181-190
-
-
Durand-Panteix, S.1
Farhat, M.2
Youlyouz-Marfak, I.3
Rouaud, P.4
Ouk-Martin, C.5
David, A.6
Faumont, N.7
Feuillard, J.8
Jayat-Vignoles, C.9
-
20
-
-
79952408951
-
Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials
-
PID: 20960500
-
Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ (2011) Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer 117(6):1262–1271. doi:10.1002/cncr.25526
-
(2011)
Cancer
, vol.117
, Issue.6
, pp. 1262-1271
-
-
Foster, N.R.1
Qi, Y.2
Shi, Q.3
Krook, J.E.4
Kugler, J.W.5
Jett, J.R.6
Molina, J.R.7
Schild, S.E.8
Adjei, A.A.9
Mandrekar, S.J.10
-
21
-
-
84858800620
-
The immune contexture in human tumours: impact on clinical outcome
-
COI: 1:CAS:528:DC%2BC38Xjslersb4%3D, PID: 22419253
-
Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306. doi:10.1038/nrc3245
-
(2012)
Nat Rev Cancer
, vol.12
, Issue.4
, pp. 298-306
-
-
Fridman, W.H.1
Pages, F.2
Sautes-Fridman, C.3
Galon, J.4
-
22
-
-
84884566872
-
Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
PID: 23813929
-
Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E, ESMO Guidelines Working Group (2013) Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(suppl 6):vi99–105. doi:10.1093/annonc/mdt178
-
(2013)
Ann Oncol
, vol.24
, Issue.6
, pp. vi99-vi105
-
-
Fruh, M.1
De Ruysscher, D.2
Popat, S.3
Crino, L.4
Peters, S.5
Felip, E.6
ESMO Guidelines Working Group7
-
23
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
COI: 1:CAS:528:DC%2BD28XhtVSnsrnK, PID: 17008531
-
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964. doi:10.1126/science.1129139
-
(2006)
Science
, vol.313
, Issue.5795
, pp. 1960-1964
-
-
Galon, J.1
Costes, A.2
Sanchez-Cabo, F.3
Kirilovsky, A.4
Mlecnik, B.5
Lagorce-Pages, C.6
Tosolini, M.7
Camus, M.8
Berger, A.9
Wind, P.10
Zinzindohoue, F.11
Bruneval, P.12
Cugnenc, P.H.13
Trajanoski, Z.14
Fridman, W.H.15
Pages, F.16
-
24
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
KEYNOTE-001 Investigators
-
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. doi:10.1056/NEJMoa1501824
-
(2015)
N Engl J Med
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
Leighl, N.4
Balmanoukian, A.S.5
Eder, J.P.6
Patnaik, A.7
Aggarwal, C.8
Gubens, M.9
Horn, L.10
Carcereny, E.11
Ahn, M.J.12
Felip, E.13
Lee, J.S.14
Hellmann, M.D.15
Hamid, O.16
Goldman, J.W.17
Soria, J.C.18
Dolled-Filhart, M.19
Rutledge, R.Z.20
Zhang, J.21
Lunceford, J.K.22
Rangwala, R.23
Lubiniecki, G.M.24
Roach, C.25
Emancipator, K.26
Gandhi, L.27
more..
-
25
-
-
84942138571
-
Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases
-
Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H (2015) Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. J Clin Oncol 33(15_suppl):abstr 8035
-
(2015)
J Clin Oncol
, vol.33
, Issue.15
, pp. abstr 8035
-
-
Goldberg, S.1
Gettinger, S.2
Mahajan, A.3
Herbst, R.4
Chiang, A.5
Tsiouris, A.6
Vortmeyer, A.7
Jilaveanu, L.8
Speaker, S.9
Madura, M.10
Rowen, E.11
Gerrish, H.12
Knapp-Perry, E.13
Yao, X.14
Chiang, V.15
Kluger, H.16
-
26
-
-
80053952183
-
Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma
-
COI: 1:CAS:528:DC%2BC3MXhtlahsrrO, PID: 21934683
-
Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, Konishi N, Hirao Y, Nonomura K, Nakajima Y (2011) Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer 105(8):1191–1196. doi:10.1038/bjc.2011.368
-
(2011)
Br J Cancer
, vol.105
, Issue.8
, pp. 1191-1196
-
-
Hotta, K.1
Sho, M.2
Fujimoto, K.3
Shimada, K.4
Yamato, I.5
Anai, S.6
Konishi, N.7
Hirao, Y.8
Nonomura, K.9
Nakajima, Y.10
-
27
-
-
84942285381
-
Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1
-
PID: 26181000
-
Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D’Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA (2015) Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 1 (9):1319–1323. doi:10.1001/jamaoncol.2015.2151
-
(2015)
JAMA Oncol
, vol.1
, Issue.9
, pp. 1319-1323
-
-
Howitt, B.E.1
Shukla, S.A.2
Sholl, L.M.3
Ritterhouse, L.L.4
Watkins, J.C.5
Rodig, S.6
Stover, E.7
Strickland, K.C.8
’Andrea, A.D.9
Wu, C.J.10
Matulonis, U.A.11
Konstantinopoulos, P.A.12
-
28
-
-
84926421308
-
Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer
-
COI: 1:CAS:528:DC%2BC2MXjtlCgs7s%3D, PID: 25384063
-
Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, Kinoshita T, Kage M, Hoshino T (2015) Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol 10(3):426–430. doi:10.1097/JTO.0000000000000414
-
(2015)
J Thorac Oncol
, vol.10
, Issue.3
, pp. 426-430
-
-
Ishii, H.1
Azuma, K.2
Kawahara, A.3
Yamada, K.4
Imamura, Y.5
Tokito, T.6
Kinoshita, T.7
Kage, M.8
Hoshino, T.9
-
29
-
-
84862769116
-
An immune-active tumor microenvironment favors clinical response to ipilimumab
-
COI: 1:CAS:528:DC%2BC38XptVGnu7w%3D, PID: 22146893
-
Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V (2012) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61(7):1019–1031. doi:10.1007/s00262-011-1172-6
-
(2012)
Cancer Immunol Immunother
, vol.61
, Issue.7
, pp. 1019-1031
-
-
Ji, R.R.1
Chasalow, S.D.2
Wang, L.3
Hamid, O.4
Schmidt, H.5
Cogswell, J.6
Alaparthy, S.7
Berman, D.8
Jure-Kunkel, M.9
Siemers, N.O.10
Jackson, J.R.11
Shahabi, V.12
-
30
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
PID: 26027431
-
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34. doi:10.1056/NEJMoa1504030
-
(2015)
N Engl J Med
, vol.373
, Issue.1
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
Grob, J.J.4
Cowey, C.L.5
Lao, C.D.6
Schadendorf, D.7
Dummer, R.8
Smylie, M.9
Rutkowski, P.10
Ferrucci, P.F.11
Hill, A.12
Wagstaff, J.13
Carlino, M.S.14
Haanen, J.B.15
Maio, M.16
Marquez-Rodas, I.17
McArthur, G.A.18
Ascierto, P.A.19
Long, G.V.20
Callahan, M.K.21
Postow, M.A.22
Grossmann, K.23
Sznol, M.24
Dreno, B.25
Bastholt, L.26
Yang, A.27
Rollin, L.M.28
Horak, C.29
Hodi, F.S.30
Wolchok, J.D.31
more..
-
31
-
-
84961249398
-
PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells
-
COI: 1:CAS:528:DC%2BC2MXhvF2lu7%2FJ, PID: 26546452
-
Mahoney KM, Sun H, Liao X, Hua P, Callea M, Greenfield EA, Hodi FS, Sharpe AH, Signoretti S, Rodig SJ, Freeman GJ (2015) PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol Res 3(12):1308–1315. doi:10.1158/2326-6066.CIR-15-0116
-
(2015)
Cancer Immunol Res
, vol.3
, Issue.12
, pp. 1308-1315
-
-
Mahoney, K.M.1
Sun, H.2
Liao, X.3
Hua, P.4
Callea, M.5
Greenfield, E.A.6
Hodi, F.S.7
Sharpe, A.H.8
Signoretti, S.9
Rodig, S.J.10
Freeman, G.J.11
-
32
-
-
84860446616
-
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
-
COI: 1:CAS:528:DC%2BC38Xmslyhsb4%3D, PID: 22456429
-
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459–465. doi:10.1016/S1470-2045(12)70090-6
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 459-465
-
-
Margolin, K.1
Ernstoff, M.S.2
Hamid, O.3
Lawrence, D.4
McDermott, D.5
Puzanov, I.6
Wolchok, J.D.7
Clark, J.I.8
Sznol, M.9
Logan, T.F.10
Richards, J.11
Michener, T.12
Balogh, A.13
Heller, K.N.14
Hodi, F.S.15
-
33
-
-
84946607195
-
Nivolumab versus everolimus in advanced renal-cell carcinoma
-
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. doi:10.1056/NEJMoa1510665
-
(2015)
N Engl J Med
-
-
Motzer, R.J.1
Escudier, B.2
McDermott, D.F.3
George, S.4
Hammers, H.J.5
Srinivas, S.6
Tykodi, S.S.7
Sosman, J.A.8
Procopio, G.9
Plimack, E.R.10
Castellano, D.11
Choueiri, T.K.12
Gurney, H.13
Donskov, F.14
Bono, P.15
Wagstaff, J.16
Gauler, T.C.17
Ueda, T.18
Tomita, Y.19
Schutz, F.A.20
Kollmannsberger, C.21
Larkin, J.22
Ravaud, A.23
Simon, J.S.24
Xu, L.A.25
Waxman, I.M.26
Sharma, P.27
CheckMate, I.28
more..
-
34
-
-
0018636116
-
CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival
-
COI: 1:STN:280:DyaL3c%2FksVKitQ%3D%3D, PID: 227582
-
Nugent JL, Bunn PA Jr, Matthews MJ, Ihde DC, Cohen MH, Gazdar A, Minna JD (1979) CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 44(5):1885–1893
-
(1979)
Cancer
, vol.44
, Issue.5
, pp. 1885-1893
-
-
Nugent, J.L.1
Bunn, P.A.2
Matthews, M.J.3
Ihde, D.C.4
Cohen, M.H.5
Gazdar, A.6
Minna, J.D.7
-
35
-
-
84939548996
-
Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028
-
Ott P, Fernandez M, Hiret S, Kim D, Moss R, Winser T, Yuan S, Cheng J, Piperdi B, Mehnert J (2015) Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol 33(15_suppl):abstr 7502
-
(2015)
J Clin Oncol
, vol.33
, Issue.15
, pp. abstr 7502
-
-
Ott, P.1
Fernandez, M.2
Hiret, S.3
Kim, D.4
Moss, R.5
Winser, T.6
Yuan, S.7
Cheng, J.8
Piperdi, B.9
Mehnert, J.10
-
36
-
-
29144514645
-
Effector memory T cells, early metastasis, and survival in colorectal cancer
-
COI: 1:CAS:528:DC%2BD2MXhtlarsrrE, PID: 16371631
-
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654–2666. doi:10.1056/NEJMoa051424
-
(2005)
N Engl J Med
, vol.353
, Issue.25
, pp. 2654-2666
-
-
Pages, F.1
Berger, A.2
Camus, M.3
Sanchez-Cabo, F.4
Costes, A.5
Molidor, R.6
Mlecnik, B.7
Kirilovsky, A.8
Nilsson, M.9
Damotte, D.10
Meatchi, T.11
Bruneval, P.12
Cugnenc, P.H.13
Trajanoski, Z.14
Fridman, W.H.15
Galon, J.16
-
37
-
-
0031906013
-
Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study
-
COI: 1:STN:280:DyaK1c7kslCnug%3D%3D, PID: 9488124
-
Postmus PE, Haaxma-Reiche H, Gregor A, Groen HJ, Lewinski T, Scolard T, Kirkpatrick A, Curran D, Sahmoud T, Giaccone G (1998) Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol 46(1):29–32
-
(1998)
Radiother Oncol
, vol.46
, Issue.1
, pp. 29-32
-
-
Postmus, P.E.1
Haaxma-Reiche, H.2
Gregor, A.3
Groen, H.J.4
Lewinski, T.5
Scolard, T.6
Kirkpatrick, A.7
Curran, D.8
Sahmoud, T.9
Giaccone, G.10
-
38
-
-
84946434271
-
The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer
-
COI: 1:CAS:528:DC%2BC2MXhvVeqs7bF, PID: 26541760
-
Qu QX, Huang Q, Shen Y, Zhu YB, Zhang XG (2016) The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer. Tumour Biol 37(4):5031–5037. doi:10.1007/s13277-015-4066-y
-
(2016)
Tumour Biol
, vol.37
, Issue.4
, pp. 5031-5037
-
-
Qu, Q.X.1
Huang, Q.2
Shen, Y.3
Zhu, Y.B.4
Zhang, X.G.5
-
39
-
-
84884530232
-
The first survival score for patients with brain metastases from small cell lung cancer (SCLC)
-
PID: 23871680
-
Rades D, Dziggel L, Segedin B, Oblak I, Nagy V, Marita A, Schild SE (2013) The first survival score for patients with brain metastases from small cell lung cancer (SCLC). Clin Neurol Neurosurg 115(10):2029–2032. doi:10.1016/j.clineuro.2013.06.019
-
(2013)
Clin Neurol Neurosurg
, vol.115
, Issue.10
, pp. 2029-2032
-
-
Rades, D.1
Dziggel, L.2
Segedin, B.3
Oblak, I.4
Nagy, V.5
Marita, A.6
Schild, S.E.7
-
40
-
-
84924901863
-
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
-
COI: 1:CAS:528:DC%2BC2MXjtFShs7s%3D, PID: 25704439
-
Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16(3):257–265. doi:10.1016/S1470-2045(15)70054-9
-
(2015)
Lancet Oncol
, vol.16
, Issue.3
, pp. 257-265
-
-
Rizvi, N.A.1
Mazieres, J.2
Planchard, D.3
Stinchcombe, T.E.4
Dy, G.K.5
Antonia, S.J.6
Horn, L.7
Lena, H.8
Minenza, E.9
Mennecier, B.10
Otterson, G.A.11
Campos, L.T.12
Gandara, D.R.13
Levy, B.P.14
Nair, S.G.15
Zalcman, G.16
Wolf, J.17
Souquet, P.J.18
Baldini, E.19
Cappuzzo, F.20
Chouaid, C.21
Dowlati, A.22
Sanborn, R.23
Lopez-Chavez, A.24
Grohe, C.25
Huber, R.M.26
Harbison, C.T.27
Baudelet, C.28
Lestini, B.J.29
Ramalingam, S.S.30
more..
-
41
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
COI: 1:CAS:528:DC%2BC2MXisFGqsLg%3D, PID: 25399552
-
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330. doi:10.1056/NEJMoa1412082
-
(2015)
N Engl J Med
, vol.372
, Issue.4
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
Dutriaux, C.4
Maio, M.5
Mortier, L.6
Hassel, J.C.7
Rutkowski, P.8
McNeil, C.9
Kalinka-Warzocha, E.10
Savage, K.J.11
Hernberg, M.M.12
Lebbe, C.13
Charles, J.14
Mihalcioiu, C.15
Chiarion-Sileni, V.16
Mauch, C.17
Cognetti, F.18
Arance, A.19
Schmidt, H.20
Schadendorf, D.21
Gogas, H.22
Lundgren-Eriksson, L.23
Horak, C.24
Sharkey, B.25
Waxman, I.M.26
Atkinson, V.27
Ascierto, P.A.28
more..
-
42
-
-
84906818599
-
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer
-
COI: 1:CAS:528:DC%2BC2cXitVWqsrfE, PID: 24978188
-
Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Chmielecki J, Ali SM, Elvin J, Morosini D, Miller VA, Stephens PJ (2014) Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol 67(9):772–776. doi:10.1136/jclinpath-2014-202447
-
(2014)
J Clin Pathol
, vol.67
, Issue.9
, pp. 772-776
-
-
Ross, J.S.1
Wang, K.2
Elkadi, O.R.3
Tarasen, A.4
Foulke, L.5
Sheehan, C.E.6
Otto, G.A.7
Palmer, G.8
Yelensky, R.9
Lipson, D.10
Chmielecki, J.11
Ali, S.M.12
Elvin, J.13
Morosini, D.14
Miller, V.A.15
Stephens, P.J.16
-
43
-
-
34547937885
-
Prophylactic cranial irradiation in extensive small-cell lung cancer
-
COI: 1:CAS:528:DC%2BD2sXptFKru7s%3D, PID: 17699816
-
Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S, EORTC Radiation Oncology Group, Lung Cancer Group (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357(7):664–672. doi:10.1056/NEJMoa071780
-
(2007)
N Engl J Med
, vol.357
, Issue.7
, pp. 664-672
-
-
Slotman, B.1
Faivre-Finn, C.2
Kramer, G.3
Rankin, E.4
Snee, M.5
Hatton, M.6
Postmus, P.7
Collette, L.8
Musat, E.9
Senan, S.10
EORTC Radiation Oncology Group11
Lung Cancer Group12
-
44
-
-
84918828514
-
Genetic basis for clinical response to CTLA-4 blockade in melanoma
-
PID: 25409260
-
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189–2199. doi:10.1056/NEJMoa1406498
-
(2014)
N Engl J Med
, vol.371
, Issue.23
, pp. 2189-2199
-
-
Snyder, A.1
Makarov, V.2
Merghoub, T.3
Yuan, J.4
Zaretsky, J.M.5
Desrichard, A.6
Walsh, L.A.7
Postow, M.A.8
Wong, P.9
Ho, T.S.10
Hollmann, T.J.11
Bruggeman, C.12
Kannan, K.13
Li, Y.14
Elipenahli, C.15
Liu, C.16
Harbison, C.T.17
Wang, L.18
Ribas, A.19
Wolchok, J.D.20
Chan, T.A.21
more..
-
45
-
-
84863020427
-
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases
-
PID: 22203767
-
Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2011) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. doi:10.1200/JCO.2011.38.0527
-
(2011)
J Clin Oncol
-
-
Sperduto, P.W.1
Kased, N.2
Roberge, D.3
Xu, Z.4
Shanley, R.5
Luo, X.6
Sneed, P.K.7
Chao, S.T.8
Weil, R.J.9
Suh, J.10
Bhatt, A.11
Jensen, A.W.12
Brown, P.D.13
Shih, H.A.14
Kirkpatrick, J.15
Gaspar, L.E.16
Fiveash, J.B.17
Chiang, V.18
Knisely, J.P.19
Sperduto, C.M.20
Lin, N.21
Mehta, M.22
more..
-
46
-
-
84946587063
-
Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment
-
PID: 25949877
-
Tan KW, Evrard M, Tham M, Hong M, Huang C, Kato M, Prevost-Blondel A, Donnadieu E, Ng LG, Abastado JP (2015) Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment. Oncoimmunology 4(2):e978709. doi:10.4161/2162402X.2014.978709
-
(2015)
Oncoimmunology
, vol.4
, Issue.2
-
-
Tan, K.W.1
Evrard, M.2
Tham, M.3
Hong, M.4
Huang, C.5
Kato, M.6
Prevost-Blondel, A.7
Donnadieu, E.8
Ng, L.G.9
Abastado, J.P.10
-
47
-
-
84904024273
-
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
-
COI: 1:CAS:528:DC%2BC2cXhs12gtbzK, PID: 24714771
-
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20(19):5064–5074. doi:10.1158/1078-0432.CCR-13-3271
-
(2014)
Clin Cancer Res
, vol.20
, Issue.19
, pp. 5064-5074
-
-
Taube, J.M.1
Klein, A.2
Brahmer, J.R.3
Xu, H.4
Pan, X.5
Kim, J.H.6
Chen, L.7
Pardoll, D.M.8
Topalian, S.L.9
Anders, R.A.10
-
48
-
-
53549123079
-
Immune-mediated dormancy: an equilibrium with cancer
-
COI: 1:CAS:528:DC%2BD1cXht1amsbvJ, PID: 18515327
-
Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ (2008) Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 84(4):988–993. doi:10.1189/jlb.1107774
-
(2008)
J Leukoc Biol
, vol.84
, Issue.4
, pp. 988-993
-
-
Teng, M.W.1
Swann, J.B.2
Koebel, C.M.3
Schreiber, R.D.4
Smyth, M.J.5
-
49
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
COI: 1:CAS:528:DC%2BC38XhtV2rs7fN, PID: 22658127
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. doi:10.1056/NEJMoa1200690
-
(2012)
N Engl J Med
, vol.366
, Issue.26
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
Powderly, J.D.7
Carvajal, R.D.8
Sosman, J.A.9
Atkins, M.B.10
Leming, P.D.11
Spigel, D.R.12
Antonia, S.J.13
Horn, L.14
Drake, C.G.15
Pardoll, D.M.16
Chen, L.17
Sharfman, W.H.18
Anders, R.A.19
Taube, J.M.20
McMiller, T.L.21
Xu, H.22
Korman, A.J.23
Jure-Kunkel, M.24
Agrawal, S.25
McDonald, D.26
Kollia, G.D.27
Gupta, A.28
Wigginton, J.M.29
Sznol, M.30
more..
-
50
-
-
84943516465
-
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
-
PID: 26359337
-
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207–211. doi:10.1126/science.aad0095
-
(2015)
Science
, vol.350
, Issue.6257
, pp. 207-211
-
-
Van Allen, E.M.1
Miao, D.2
Schilling, B.3
Shukla, S.A.4
Blank, C.5
Zimmer, L.6
Sucker, A.7
Hillen, U.8
Foppen, M.H.9
Goldinger, S.M.10
Utikal, J.11
Hassel, J.C.12
Weide, B.13
Kaehler, K.C.14
Loquai, C.15
Mohr, P.16
Gutzmer, R.17
Dummer, R.18
Gabriel, S.19
Wu, C.J.20
Schadendorf, D.21
Garraway, L.A.22
more..
-
51
-
-
84891534246
-
Programmed death ligand-1 expression in non-small cell lung cancer
-
COI: 1:CAS:528:DC%2BC3sXhslygs7jJ, PID: 24217091
-
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94(1):107–116. doi:10.1038/labinvest.2013.130
-
(2014)
Lab Invest
, vol.94
, Issue.1
, pp. 107-116
-
-
Velcheti, V.1
Schalper, K.A.2
Carvajal, D.E.3
Anagnostou, V.K.4
Syrigos, K.N.5
Sznol, M.6
Herbst, R.S.7
Gettinger, S.N.8
Chen, L.9
Rimm, D.L.10
-
52
-
-
84961163040
-
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
-
COI: 1:CAS:528:DC%2BC28XksVWlsLs%3D, PID: 26972336
-
Webb JR, Milne K, Kroeger DR, Nelson BH (2016) PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol 141(2):293–302. doi:10.1016/j.ygyno.2016.03.008
-
(2016)
Gynecol Oncol
, vol.141
, Issue.2
, pp. 293-302
-
-
Webb, J.R.1
Milne, K.2
Kroeger, D.R.3
Nelson, B.H.4
-
53
-
-
84881536183
-
Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry
-
PID: 23611589
-
Woehrer A (2013) Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry. Clin Neuropathol 32(4):269–285. doi:10.5414/NP300600
-
(2013)
Clin Neuropathol
, vol.32
, Issue.4
, pp. 269-285
-
-
Woehrer, A.1
-
54
-
-
70450248574
-
The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry
-
PID: 19562257
-
Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rossler K, Hainfellner JA (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95(3):401–411. doi:10.1007/s11060-009-9938-9
-
(2009)
J Neurooncol
, vol.95
, Issue.3
, pp. 401-411
-
-
Wohrer, A.1
Waldhor, T.2
Heinzl, H.3
Hackl, M.4
Feichtinger, J.5
Gruber-Mosenbacher, U.6
Kiefer, A.7
Maier, H.8
Motz, R.9
Reiner-Concin, A.10
Richling, B.11
Idriceanu, C.12
Scarpatetti, M.13
Sedivy, R.14
Bankl, H.C.15
Stiglbauer, W.16
Preusser, M.17
Rossler, K.18
Hainfellner, J.A.19
-
55
-
-
84930919966
-
Tumor-infiltrating CD45RO memory cells are associated with a favorable prognosis breast cancer
-
PID: 26071015
-
Yajima R, Yajima T, Fujii T, Yanagita Y, Fujisawa T, Miyamoto T, Tsutsumi S, Iijima M, Kuwano H (2015) Tumor-infiltrating CD45RO memory cells are associated with a favorable prognosis breast cancer. Breast Cancer. doi:10.1007/s12282-015-0622-y
-
(2015)
Breast Cancer
-
-
Yajima, R.1
Yajima, T.2
Fujii, T.3
Yanagita, Y.4
Fujisawa, T.5
Miyamoto, T.6
Tsutsumi, S.7
Iijima, M.8
Kuwano, H.9
-
56
-
-
84908075718
-
Risk factors for brain metastases in completely resected small cell lung cancer: a retrospective study to identify patients most likely to benefit from prophylactic cranial irradiation
-
PID: 25239373
-
Zhu H, Bi Y, Han A, Luo J, Li M, Shi F, Kong L, Yu J (2014) Risk factors for brain metastases in completely resected small cell lung cancer: a retrospective study to identify patients most likely to benefit from prophylactic cranial irradiation. Radiat Oncol 9:216. doi:10.1186/1748-717X-9-216
-
(2014)
Radiat Oncol
, vol.9
, pp. 216
-
-
Zhu, H.1
Bi, Y.2
Han, A.3
Luo, J.4
Li, M.5
Shi, F.6
Kong, L.7
Yu, J.8
-
57
-
-
84907484156
-
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models
-
COI: 1:CAS:528:DC%2BC2cXhsFChtbjO, PID: 25082815
-
Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74(18):5057–5069. doi:10.1158/0008-5472.CAN-13-3723
-
(2014)
Cancer Res
, vol.74
, Issue.18
, pp. 5057-5069
-
-
Zhu, Y.1
Knolhoff, B.L.2
Meyer, M.A.3
Nywening, T.M.4
West, B.L.5
Luo, J.6
Wang-Gillam, A.7
Goedegebuure, S.P.8
Linehan, D.C.9
DeNardo, D.G.10
|